Obstetrics/Gynecology
RSSArticles
-
Researchers Study COVID-19 Vaccine Outreach to Pregnant Women
The results of a recent study highlight the gaps in COVID-19 vaccination among pregnant women in the United States. Although pregnant women are at increased risk for severe illness and death from the disease, many remain unvaccinated. -
Reproductive Health Organizations Help Vaccinate Patients, Communities
Planned Parenthood and other reproductive health organizations have initiated COVID-19 vaccine outreach for their patients and communities. In addition to encouraging staff and patients to take the vaccine, the organizations have taken a positive COVID-19 vaccine message to minority communities and others hit hard by the pandemic. -
Evaluation of an Inpatient Postpartum Human Papillomavirus Immunization Program
In this cohort study, results from two years of an inpatient postpartum HPV vaccination program are presented. Overall, their results show an increased rate of immunization (hazard ratio of 2.51) and an increased proportion of women completing the vaccination series (35.8% of those receiving an inpatient dose completed the series compared to 9.3% of those who did not get the inpatient dose).
-
When Is the Ideal Time in the Menstrual Cycle for IUD Insertion?
In this retrospective cohort study, women using the levonorgestrel intrauterine device for noncontraceptive indications had higher expulsion rates (38% vs. 17%, P = 0.03) when insertion occurred on day 1 to day 8 of the menstrual cycle compared to after day 8.
-
The Association Between SSRIs and Congenital Anomalies
In this synthesis involving 15 meta-analytic studies, four studies demonstrated an association between paroxetine use during pregnancy and increased risk of major congenital anomalies (relative risk [RR], 1.18 [95% confidence interval (CI), 1.05, 1.32] to 1.29 [95% CI, 1.11-1.49]). For all selective serotonin reuptake inhibitors (SSRIs), the RR for major anomalies (1.10 [95% CI, 1.03, 1.16] to 1.27 [95% CI, 1.09, 1.47]) and cardiac defects (1.06 [95% CI, 0.94, 1.18] to 1.36 [95% CI, 0.61, 3.04]) were increased. This meta-analysis suggests an increased risk of cardiac and major anomalies with SSRI use, but the results should be interpreted with caution, since all included studies were meta-analyses of retrospective cohort studies.
-
Management of Heavy Menstrual Bleeding: Levonorgestrel-Releasing Intrauterine System vs. Endometrial Ablation
In this multicenter, randomized, noninferiority trial among patients aged 34 years and older with heavy menstrual bleeding, the levonorgestrel-releasing intrauterine system did not meet the noninferiority threshold when compared to endometrial ablation for mean blood loss at 24 months following intervention. Both interventions did lead to large decreases in blood loss and comparable satisfaction and quality-of-life scores.
-
New Program for LGBTQ Youth Is Designed to Reduce Unintended Pregnancies
A researcher created a new program for LGBTQ youth based on the idea that this population experiences more difficulty accessing reproductive healthcare, partly because of problems related to their choice of pronouns and names. The program addresses which contraceptives and intrauterine devices transgender boys can use, and which are effective and do not interfere with their hormone treatment. -
Study Finds No Differences in Pregnancy Plans Between Young Black and White Women
Black and white young women share similar desires to avoid pregnancy and similar pregnancy plans, but Black women were much less likely to be pronatal, advocating for a higher birth rate, than were white women, new research revealed. The unintended pregnancy rate is 2.5 times higher for Black women than for white women, which raises questions about why this difference occurs. -
Research Shows Low-Sensitivity Pregnancy Test Works Well After Medication Abortion
New research shows using a low-sensitivity pregnancy test after a medication abortion is both accurate and safe. The 1,000 mIU/mL low-sensitivity pregnancy test or the five-level multilevel pregnancy test can be used safely without a visit to a provider’s office or clinic. -
New Oral Contraceptive Holds Promise of Few or No Blood Clots, Other Adverse Effects
Recent research has shown that a new combined oral contraceptive has high efficacy, cycle control, and safety, even among a diverse American population that included women with a body mass index of 35 kg/m2. The medication contains estetrol (a novel estrogen) and drospirenone.